For patients with T2D, semaglutide seems to confer some advantage over empagliflozin in terms of mortality and CV event risks.

Q: My doctor is suggesting that I try taking one of those new weight loss drugs -- off-label -- to help me cut down on my alcohol consumption. Does this make any sense? -- Pat R., Ann Arbor, Michigan ...

Weight-loss surgery significantly reduces the risk of psychiatric issues like cognitive decline, anxiety, and substance use ...

Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June ...

The UK’s medicines regulator has received over 100 reports of deaths potentially associated with widely used weight loss ...

Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

A new study has found that people with type 2 diabetes who take semaglutide—a drug commonly known by its brand names Ozempic ...

At the same time, and likely because of this, data shows that demand for bariatric surgery has plunged, dropping nearly 26 ...

Novo Nordisk gets CHMP backing for oral GLP-1 agonist Rybelsus in its marketing battle with Eli Lilly, plus positive opinions for Bayer’s diabetes drug Nubeqa, Emergent’s cholera vaccine, and more ...

Eli Lilly has followed Novo Nordisk in announcing a big investment in its manufacturing network, intended to meet anticipated strong future demand for diabetes and obesity drugs.

Bariatric surgery shows better real-life results than GLP-1s in a study: the scalpel achieves five times more weight loss ...

Denosumab (Prolia) is a leading treatment for osteoporosis, but the rapid bone loss that can occur after discontinuing the ...